Morgan Stanley
FLGT icon

Morgan Stanley’s Fulgent Genetics FLGT Stock Holding History

Morgan Stanley’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.06M Sell
192,403
-122,850
-39% -$2.67M ﹤0.01% 4462
2025
Q4 		$8.28M Buy
315,253
+38,695
+14% +$1M ﹤0.01% 3765
2025
Q3 		$6.25M Buy
276,558
+52,484
+23% +$1.08M ﹤0.01% 3966
2025
Q2 		$4.45M Buy
224,074
+43,936
+24% +$856K ﹤0.01% 4143
2025
Q1 		$3.04M Sell
180,138
-361,834
-67% -$6.16M ﹤0.01% 4315
2024
Q4 		$10M Buy
541,972
+74,640
+16% +$1.46M ﹤0.01% 3414
2024
Q3 		$10.2M Buy
467,332
+98,199
+27% +$2.2M ﹤0.01% 3422
2024
Q2 		$7.24M Buy
369,133
+148,885
+68% +$3.11M ﹤0.01% 3585
2024
Q1 		$4.78M Sell
220,248
-306,324
-58% -$7.61M ﹤0.01% 3950
2023
Q4 		$15.2M Buy
526,572
+276,215
+110% +$7.39M ﹤0.01% 3586
2023
Q3 		$6.69M Buy
250,357
+29,749
+13% +$1.02M ﹤0.01% 3489
2023
Q2 		$8.17M Sell
220,608
-82,299
-27% -$2.87M ﹤0.01% 3354
2023
Q1 		$9.46M Buy
302,907
+38,819
+15% +$1.25M ﹤0.01% 3200
2022
Q4 		$7.86M Sell
264,088
-25,199
-9% -$902K ﹤0.01% 3305
2022
Q3 		$11M Buy
289,287
+47,227
+20% +$2.37M ﹤0.01% 2855
2022
Q2 		$13.2M Buy
242,060
+28,270
+13% +$1.55M ﹤0.01% 2758
2022
Q1 		$13.3M Buy
213,790
+37,266
+21% +$2.45M ﹤0.01% 2558
2021
Q4 		$17.8M Buy
176,524
+12,889
+8% +$1.13M ﹤0.01% 2286
2021
Q3 		$14.7M Sell
163,635
-198,826
-55% -$18.1M ﹤0.01% 2430
2021
Q2 		$33.4M Sell
362,461
-195,739
-35% -$15.6M ﹤0.01% 1638
2021
Q1 		$53.9M Buy
558,200
+292,953
+110% +$30.2M 0.01% 1129
2020
Q4 		$13.8M Buy
265,247
+147,894
+126% +$6.18M ﹤0.01% 2179
2020
Q3 		$4.7M Sell
117,353
-36,258
-24% -$1.13M ﹤0.01% 2778
2020
Q2 		$2.46M Buy
153,611
+104,779
+215% +$1.6M ﹤0.01% 3396
2020
Q1 		$525K Buy
48,832
+48,504
+14,788% +$676K ﹤0.01% 4342
2019
Q4 		$4K Sell
328
-5,310
-94% -$63.1K ﹤0.01% 6423
2019
Q3 		$58K Buy
5,638
+4,113
+270% +$39K ﹤0.01% 5658
2019
Q2 		$10K Buy
1,525
+1,038
+213% +$6.32K ﹤0.01% 6124
2019
Q1 		$3K Sell
487
-23
-5% -$105 ﹤0.01% 6397
2018
Q4 		$2K Sell
510
-1,490
-75% -$5.23K ﹤0.01% 6411
2018
Q3 		$8K Hold
2,000
– – ﹤0.01% 6351
2018
Q2 		$8K Hold
2,000
– – ﹤0.01% 6352
2018
Q1 		$8K Sell
2,000
-2,185
-52% -$9.62K ﹤0.01% 6307
2017
Q4 		$18K Buy
4,185
+2,185
+109% +$8.37K ﹤0.01% 6100
2017
Q3 		$10K Sell
2,000
-265
-12% -$1.52K ﹤0.01% 6171
2017
Q2 		$15K Sell
2,265
-4,826
-68% -$38.9K ﹤0.01% 6150
2017
Q1 		$78K Sell
7,091
-5,244
-43% -$62K ﹤0.01% 5690
2016
Q4 		$143K Buy
12,335
+11,835
+2,367% +$112K ﹤0.01% 5461
2016
Q3 		$5K Buy
+500
New +$4.6K ﹤0.01% 6230

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley's FLGT Position: Q1 2026 in Review

Morgan Stanley reduced its Fulgent Genetics (FLGT) stake by 39% in Q1 2026, selling an estimated $2.67M and leaving 192,403 shares worth $3.06M. The position accounts for ﹤0.01% of the portfolio, ranked #4462.

Morgan Stanley first reported a position in FLGT in Q3 2016 and has held it in 39 quarters since. The position peaked at $53.9M in Q1 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • Morgan Stanley held 192,403 shares of Fulgent Genetics worth $3.06M as of Q1 2026.
  • Morgan Stanley sold 122,850 Fulgent Genetics shares in Q1 2026, an estimated $2.67M.
  • Fulgent Genetics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #4462 holding.
  • Morgan Stanley first reported a position in Fulgent Genetics in Q3 2016 and has held it in 39 quarters since.
  • Morgan Stanley's Fulgent Genetics position peaked at $53.9M in Q1 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.